Acidosis promotes the metastatic colonization of lung cancer via remodeling of the extracellular matrix and vasculogenic mimicry
Int J Oncol. 2023 Dec;63(6):136. doi: 10.3892/ijo.2023.5584. Epub 2023 Oct 27.ABSTRACTAcidosis is a hallmark of the tumor microenvironment caused by the metabolic switch from glucose oxidative phosphorylation to glycolysis. It has been associated with tumor growth and progression; however, the precise mechanism governing how acidosis promotes metastatic dissemination has yet to be elucidated. In the present study, a long‑term acidosis model was established using patient‑derived lung cancer cells, to identify critical components of metastatic colonization via transcriptome profiling combined with both in vitro and in vi...
Source: International Journal of Oncology - October 27, 2023 Category: Cancer & Oncology Authors: Wan-Yi Shie Pin-Hsuan Chu Mark Yen-Ping Kuo Huei-Wen Chen Meng-Tie Lin Xuan-Jie Su Yi-Ling Hong Han-Yi Elizabeth Chou Source Type: research

[Corrigendum] Fully human VEGFR2 monoclonal antibody BC001 attenuates tumor angiogenesis and inhibits tumor growth
Int J Oncol. 2023 Dec;63(6):135. doi: 10.3892/ijo.2023.5583. Epub 2023 Oct 27.ABSTRACTSubsequently to the publication of the above paper, an interested reader drew to the authors' attention that, for the scratch wound assay experiments shown in Fig. 1 on p. 2413, the panels showing the '0 h' experiments for the respective incubations with VEGF or BC001 were apparently identical. The authors were able to re‑examine their original data files, and realized that this figure had been inadverently assembled incorrectly. The revised version of Fig. 1, containing the correct data for the '0 h / BC001' panel, is shown below. Note...
Source: International Journal of Oncology - October 27, 2023 Category: Cancer & Oncology Authors: Zi-Xue Xuan Lin-Na Li Qi Zhang Cheng-Wang Xu De-Xuan Yang Ye Yuan Ying-Hong An Shan-Shan Wang Xiao-Wen Li Shou-Jun Yuan Source Type: research

Novel insights into the ecDNA formation mechanism involving MSH3 in methotrexate ‑resistant human colorectal cancer cells
In conclusion, the present study revealed a novel mechanism involving MSH3 in the regulation of ecDNAs by DSB repair, which will have clinical value in the treatment of ecDNA‑based drug resistance in cancer.PMID:37888748 | DOI:10.3892/ijo.2023.5582 (Source: International Journal of Oncology)
Source: International Journal of Oncology - October 27, 2023 Category: Cancer & Oncology Authors: Xu Wang Yanan Qu Ruonan Xing Jing Zhou Yanghe Liu Huishu Zhang Jing Zhu Jinfa Ma Xiaobo Cui Tiantian Song Shukai Xing Guohua Ji Peng Liu Wenjing Sun Songbin Fu Xiangning Meng Source Type: research

Tripartite motif containing 33 demonstrated anticancer effect by degrading c ‑Myc: Limitation of glutamine metabolism and proliferation in endometrial carcinoma cells
Int J Oncol. 2023 Dec;63(6):133. doi: 10.3892/ijo.2023.5581. Epub 2023 Oct 20.ABSTRACTTripartite motif containing 33 (TRIM33) has been reported to be involved in various tumor progression. However, its role in endometrial carcinoma (EC) remains to be elucidated. By mining the publicly available databases UALCAN and TIMER, low expression of TRIM33 was found in tumor tissues of EC patients. Clinically, downregulation of TRIM33 in EC tissues was positively correlated with the extensive muscle invasion and poor differentiation grade. In vitro, experiments performed on human HEC‑1‑A and AN3CA cells showed that overexpressio...
Source: International Journal of Oncology - October 20, 2023 Category: Cancer & Oncology Authors: Yue Qi Ningye Ma Jin Zhang Source Type: research

Tripartite motif containing 33 demonstrated anticancer effect by degrading c ‑Myc: Limitation of glutamine metabolism and proliferation in endometrial carcinoma cells
Int J Oncol. 2023 Dec;63(6):133. doi: 10.3892/ijo.2023.5581. Epub 2023 Oct 20.ABSTRACTTripartite motif containing 33 (TRIM33) has been reported to be involved in various tumor progression. However, its role in endometrial carcinoma (EC) remains to be elucidated. By mining the publicly available databases UALCAN and TIMER, low expression of TRIM33 was found in tumor tissues of EC patients. Clinically, downregulation of TRIM33 in EC tissues was positively correlated with the extensive muscle invasion and poor differentiation grade. In vitro, experiments performed on human HEC‑1‑A and AN3CA cells showed that overexpressio...
Source: International Journal of Oncology - October 20, 2023 Category: Cancer & Oncology Authors: Yue Qi Ningye Ma Jin Zhang Source Type: research

Tripartite motif containing 33 demonstrated anticancer effect by degrading c ‑Myc: Limitation of glutamine metabolism and proliferation in endometrial carcinoma cells
Int J Oncol. 2023 Dec;63(6):133. doi: 10.3892/ijo.2023.5581. Epub 2023 Oct 20.ABSTRACTTripartite motif containing 33 (TRIM33) has been reported to be involved in various tumor progression. However, its role in endometrial carcinoma (EC) remains to be elucidated. By mining the publicly available databases UALCAN and TIMER, low expression of TRIM33 was found in tumor tissues of EC patients. Clinically, downregulation of TRIM33 in EC tissues was positively correlated with the extensive muscle invasion and poor differentiation grade. In vitro, experiments performed on human HEC‑1‑A and AN3CA cells showed that overexpressio...
Source: International Journal of Oncology - October 20, 2023 Category: Cancer & Oncology Authors: Yue Qi Ningye Ma Jin Zhang Source Type: research

Tripartite motif containing 33 demonstrated anticancer effect by degrading c ‑Myc: Limitation of glutamine metabolism and proliferation in endometrial carcinoma cells
Int J Oncol. 2023 Dec;63(6):133. doi: 10.3892/ijo.2023.5581. Epub 2023 Oct 20.ABSTRACTTripartite motif containing 33 (TRIM33) has been reported to be involved in various tumor progression. However, its role in endometrial carcinoma (EC) remains to be elucidated. By mining the publicly available databases UALCAN and TIMER, low expression of TRIM33 was found in tumor tissues of EC patients. Clinically, downregulation of TRIM33 in EC tissues was positively correlated with the extensive muscle invasion and poor differentiation grade. In vitro, experiments performed on human HEC‑1‑A and AN3CA cells showed that overexpressio...
Source: International Journal of Oncology - October 20, 2023 Category: Cancer & Oncology Authors: Yue Qi Ningye Ma Jin Zhang Source Type: research

Tripartite motif containing 33 demonstrated anticancer effect by degrading c ‑Myc: Limitation of glutamine metabolism and proliferation in endometrial carcinoma cells
Int J Oncol. 2023 Dec;63(6):133. doi: 10.3892/ijo.2023.5581. Epub 2023 Oct 20.ABSTRACTTripartite motif containing 33 (TRIM33) has been reported to be involved in various tumor progression. However, its role in endometrial carcinoma (EC) remains to be elucidated. By mining the publicly available databases UALCAN and TIMER, low expression of TRIM33 was found in tumor tissues of EC patients. Clinically, downregulation of TRIM33 in EC tissues was positively correlated with the extensive muscle invasion and poor differentiation grade. In vitro, experiments performed on human HEC‑1‑A and AN3CA cells showed that overexpressio...
Source: International Journal of Oncology - October 20, 2023 Category: Cancer & Oncology Authors: Yue Qi Ningye Ma Jin Zhang Source Type: research

Tripartite motif containing 33 demonstrated anticancer effect by degrading c ‑Myc: Limitation of glutamine metabolism and proliferation in endometrial carcinoma cells
Int J Oncol. 2023 Dec;63(6):133. doi: 10.3892/ijo.2023.5581. Epub 2023 Oct 20.ABSTRACTTripartite motif containing 33 (TRIM33) has been reported to be involved in various tumor progression. However, its role in endometrial carcinoma (EC) remains to be elucidated. By mining the publicly available databases UALCAN and TIMER, low expression of TRIM33 was found in tumor tissues of EC patients. Clinically, downregulation of TRIM33 in EC tissues was positively correlated with the extensive muscle invasion and poor differentiation grade. In vitro, experiments performed on human HEC‑1‑A and AN3CA cells showed that overexpressio...
Source: International Journal of Oncology - October 20, 2023 Category: Cancer & Oncology Authors: Yue Qi Ningye Ma Jin Zhang Source Type: research

Journey of CAR T ‑cells: Emphasising the concepts and advancements in breast cancer (Review)
Int J Oncol. 2023 Dec;63(6):130. doi: 10.3892/ijo.2023.5578. Epub 2023 Oct 13.ABSTRACTCancer is the primary and one of the most prominent causes of the rising global mortality rate, accounting for nearly 10 million deaths annually. Specific methods have been devised to cure cancerous tumours. Effective therapeutic approaches must be developed, both at the cellular and genetic level. Immunotherapy offers promising results by providing sustained remission to patients with refractory malignancies. Genetically modified T‑lymphocytic cells have emerged as a novel therapeutic approach for the treatment of solid tumours, haemat...
Source: International Journal of Oncology - October 13, 2023 Category: Cancer & Oncology Authors: Mohd Adnan Kausar Sadaf Anwar Hemat El-Sayed El-Horany Farida Habib Khan Neetu Tyagi Mohammad Zeeshan Najm None Sadaf Alaa Abdulaziz Eisa Chandrajeet Dhara Saumyatika Gantayat Source Type: research

CUDC ‑101 is a potential target inhibitor for the EGFR‑overexpression bladder cancer cells
Int J Oncol. 2023 Dec;63(6):131. doi: 10.3892/ijo.2023.5579. Epub 2023 Oct 13.ABSTRACTBladder cancer is one of the most common urological malignancies worldwide. The molecular mechanism underlying its development is complex, but its carcinogenesis has been proposed to occur with cell proliferation and resistance to apoptosis, driven by the signaling activity of abundant EGFR and receptor tyrosine‑protein kinase erbB‑2. In the present study, T24 bladder cancer cell lines with EGFR‑overexpression were constructed, before the multi‑target inhibitor CUDC‑101 was used to investigate its potential as a targeted therape...
Source: International Journal of Oncology - October 13, 2023 Category: Cancer & Oncology Authors: Zhenxing Wang Lanxin Li Chunhong Chu Xiangkai Wei Qian Liu Rui Wang Guoliang Zhang Guangyao Wu Ying Wang Lei An Xiaodong Li Source Type: research

Journey of CAR T ‑cells: Emphasising the concepts and advancements in breast cancer (Review)
Int J Oncol. 2023 Dec;63(6):130. doi: 10.3892/ijo.2023.5578. Epub 2023 Oct 13.ABSTRACTCancer is the primary and one of the most prominent causes of the rising global mortality rate, accounting for nearly 10 million deaths annually. Specific methods have been devised to cure cancerous tumours. Effective therapeutic approaches must be developed, both at the cellular and genetic level. Immunotherapy offers promising results by providing sustained remission to patients with refractory malignancies. Genetically modified T‑lymphocytic cells have emerged as a novel therapeutic approach for the treatment of solid tumours, haemat...
Source: International Journal of Oncology - October 13, 2023 Category: Cancer & Oncology Authors: Mohd Adnan Kausar Sadaf Anwar Hemat El-Sayed El-Horany Farida Habib Khan Neetu Tyagi Mohammad Zeeshan Najm None Sadaf Alaa Abdulaziz Eisa Chandrajeet Dhara Saumyatika Gantayat Source Type: research

CUDC ‑101 is a potential target inhibitor for the EGFR‑overexpression bladder cancer cells
Int J Oncol. 2023 Dec;63(6):131. doi: 10.3892/ijo.2023.5579. Epub 2023 Oct 13.ABSTRACTBladder cancer is one of the most common urological malignancies worldwide. The molecular mechanism underlying its development is complex, but its carcinogenesis has been proposed to occur with cell proliferation and resistance to apoptosis, driven by the signaling activity of abundant EGFR and receptor tyrosine‑protein kinase erbB‑2. In the present study, T24 bladder cancer cell lines with EGFR‑overexpression were constructed, before the multi‑target inhibitor CUDC‑101 was used to investigate its potential as a targeted therape...
Source: International Journal of Oncology - October 13, 2023 Category: Cancer & Oncology Authors: Zhenxing Wang Lanxin Li Chunhong Chu Xiangkai Wei Qian Liu Rui Wang Guoliang Zhang Guangyao Wu Ying Wang Lei An Xiaodong Li Source Type: research

Journey of CAR T ‑cells: Emphasising the concepts and advancements in breast cancer (Review)
Int J Oncol. 2023 Dec;63(6):130. doi: 10.3892/ijo.2023.5578. Epub 2023 Oct 13.ABSTRACTCancer is the primary and one of the most prominent causes of the rising global mortality rate, accounting for nearly 10 million deaths annually. Specific methods have been devised to cure cancerous tumours. Effective therapeutic approaches must be developed, both at the cellular and genetic level. Immunotherapy offers promising results by providing sustained remission to patients with refractory malignancies. Genetically modified T‑lymphocytic cells have emerged as a novel therapeutic approach for the treatment of solid tumours, haemat...
Source: International Journal of Oncology - October 13, 2023 Category: Cancer & Oncology Authors: Mohd Adnan Kausar Sadaf Anwar Hemat El-Sayed El-Horany Farida Habib Khan Neetu Tyagi Mohammad Zeeshan Najm None Sadaf Alaa Abdulaziz Eisa Chandrajeet Dhara Saumyatika Gantayat Source Type: research

CUDC ‑101 is a potential target inhibitor for the EGFR‑overexpression bladder cancer cells
Int J Oncol. 2023 Dec;63(6):131. doi: 10.3892/ijo.2023.5579. Epub 2023 Oct 13.ABSTRACTBladder cancer is one of the most common urological malignancies worldwide. The molecular mechanism underlying its development is complex, but its carcinogenesis has been proposed to occur with cell proliferation and resistance to apoptosis, driven by the signaling activity of abundant EGFR and receptor tyrosine‑protein kinase erbB‑2. In the present study, T24 bladder cancer cell lines with EGFR‑overexpression were constructed, before the multi‑target inhibitor CUDC‑101 was used to investigate its potential as a targeted therape...
Source: International Journal of Oncology - October 13, 2023 Category: Cancer & Oncology Authors: Zhenxing Wang Lanxin Li Chunhong Chu Xiangkai Wei Qian Liu Rui Wang Guoliang Zhang Guangyao Wu Ying Wang Lei An Xiaodong Li Source Type: research